Abstract

PIOGLITAZONE MICROCAPSULES: FORMULATION AND IN VITRO - EX VIVO CHARACTERIZATION

Bhabani Shankar Nayak*, Debabrata Sahoo, Sruti Ranjan Mishra and P. Ellaiah

Abstract

Background: Pioglitazone is a thiazolidinedione class drug with hypoglycemic action to treat type 2 diabetes. Aim: The study aimed to design, prepare and evaluate the Pioglitazone microcapsules. Methods: The Pioglitazone microcapsule formulations (F1 to F6) were prepares by ionic gelation technique using hydroxy propyl methyl cellulose (HPMC-E5LV), sodium carboxy methyl cellulose (CMCLV) and Hydroxy Propyl Celluloose (HPC-SSL) as rate controlling polymer in two different ratios of 1:1 and 1:2 (Drug: polymer). The drug polymer compatibility was studied using FTIR and DSC techniques. The prepared microcapsule were evaluated for yield, particle size, shape (SEM study), wall thickness, flow property, drug content, loose surface crystal study, swelling index, percentage moisture loss, in vitro drug release and kinetic studies, stability study and mucoadhesion property. Results: The microcapsules size was small and spherical shape, with good flow properties. The FTIR and DSC study showed no such significant physical or chemical interaction was occurred between drug and polymers. All microcapsule formulations possessed good physicochemical properties. The maximum drug content was obtained with F6 (84 %). All microcapsule formulations released drug in control manner. The microcapsule formulation F6 (0.8 % Hydroxy propyl cellulose) was found to release the drug only 26 % even after 12 h in constant manner with regular fashion with good mucoadhesion, when compared to other microcapsules formulations. The optimized microcapsules were found to be stable at different storage condition. Conclusion: It could be concluded that the microcapsule formulation F6 is the best optimized formulation, which could be use for safe management of type II diabetes orally.

Keywords: Microcapsules, Mucoadhesion, Pioglitazone, hypoglycemic, Type II diabetes.